OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, ...
The scope covers prescription drugs and drug-led, drug-device combination products where the Center for Drug Evaluation and ...
Germany is the European Union’s (EU) largest pharmaceutical market by revenue and has the highest medical biotechnology ...
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human ...
AstraZeneca and insitro announced on Oct. 15, 2026, a strategic drug discovery collaboration and licensing agreement that ...
Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
As GLP-1 therapies evolve from single-agonist peptides toward dual and triple agonists, formulation and CMC teams face a more ...
In the latest installment of the PharmTech AI Pulse Check video series, Associate Editorial Director Christopher Cole is ...
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup. This week on PharmTech.com, the FDA moved to shorten first-in-human ...
On October 14, 2026, the FDA expanded the approved use of Anktiva (nogapendekin alfa inbakicept-pmln), given with Bacillus Calmette-Guérin (BCG), to include adults with high-grad ...
Boyang Wang, Immortal Dragons, discusses how the FDA’s Expedited IND Pilot must prove efficiency as sponsors chase the fastest route to valid first-in-human data. Boyang Wang, founder of Immortal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results